Jet, do you have any thoughts on price per patient per year for this drug? With 100,000 severe hypertriglyceridemia sufferers in the U.S. and Europe, even modest market penetration in this initial patient population could provide a huge amount of revenue.
Just a guess but I'd say somewhere in the range of $2000 per month for the very high risk patient. It probably will only be able to be prescribed by lipidologists, endocrinologists, and some cardiologists. t